IL152231A0 - Diazabicyclic central nervous system active agents - Google Patents

Diazabicyclic central nervous system active agents

Info

Publication number
IL152231A0
IL152231A0 IL15223101A IL15223101A IL152231A0 IL 152231 A0 IL152231 A0 IL 152231A0 IL 15223101 A IL15223101 A IL 15223101A IL 15223101 A IL15223101 A IL 15223101A IL 152231 A0 IL152231 A0 IL 152231A0
Authority
IL
Israel
Prior art keywords
nervous system
active agents
central nervous
system active
diazabicyclic
Prior art date
Application number
IL15223101A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL152231A0 publication Critical patent/IL152231A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15223101A 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents IL152231A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents
PCT/US2001/013798 WO2001081347A2 (en) 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents

Publications (1)

Publication Number Publication Date
IL152231A0 true IL152231A0 (en) 2003-05-29

Family

ID=27072208

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15223101A IL152231A0 (en) 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents
IL177316A IL177316A (en) 2000-04-27 2006-08-06 Diazabicyclic factors active in the central nervous system
IL203035A IL203035A (en) 2000-04-27 2009-12-29 Diazabicyclic compounds, pharmaceutical compositions comprising them and uses thereof in preparing medicaments for selectively controlling neurotransmitter release in mammals and for controlling pain

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL177316A IL177316A (en) 2000-04-27 2006-08-06 Diazabicyclic factors active in the central nervous system
IL203035A IL203035A (en) 2000-04-27 2009-12-29 Diazabicyclic compounds, pharmaceutical compositions comprising them and uses thereof in preparing medicaments for selectively controlling neurotransmitter release in mammals and for controlling pain

Country Status (22)

Country Link
EP (3) EP1284976A2 (no)
JP (2) JP4981232B2 (no)
KR (4) KR100947187B1 (no)
CN (3) CN102863441A (no)
AR (1) AR030421A1 (no)
AU (2) AU6655901A (no)
BG (2) BG66151B1 (no)
BR (1) BR0107246A (no)
CA (2) CA2683045A1 (no)
CZ (4) CZ302795B6 (no)
HK (1) HK1054375A1 (no)
HU (1) HUP0300602A3 (no)
IL (3) IL152231A0 (no)
MX (1) MXPA02010594A (no)
MY (3) MY137020A (no)
NO (1) NO324250B1 (no)
NZ (1) NZ521734A (no)
PE (1) PE20011305A1 (no)
PL (2) PL358340A1 (no)
SK (2) SK287658B6 (no)
TW (4) TW201141871A (no)
WO (1) WO2001081347A2 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60007552T2 (de) 1999-12-10 2004-09-23 Pfizer Products Inc., Groton PYRROLO[2,3-d]PYRIMIDIN-VERBINDUNGEN ALS PROTEIN KINASEN HEMMER
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
AU2003278529A1 (en) 2002-11-21 2004-06-15 Pfizer Products Inc. 3-amino-piperidine derivatives and processes for their preparation
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
EP1747206A1 (en) 2004-04-29 2007-01-31 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
BRPI0620126A2 (pt) * 2005-12-20 2011-11-01 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, método para modular a atividade de um receptor de gabaa, e, método sintético para fabricar um composto
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
JP5566698B2 (ja) 2007-03-23 2014-08-06 アッヴィ・インコーポレイテッド アザアダマンタンエステルおよびカーバメート誘導体ならびにそれらの使用方法
JP5665540B2 (ja) 2007-09-11 2015-02-04 アッヴィ・インコーポレイテッド オクタヒドロ−ピロロ［３，４−ｂ］ピロールｎ−オキシド
TW200932236A (en) 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
CN101918409A (zh) 2007-11-21 2010-12-15 雅培制药有限公司 联芳基取代的二氮杂双环烷衍生物
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8546401B2 (en) 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
CN101981027B (zh) 2007-12-07 2014-08-06 Abbvie德国有限责任两合公司 氨基甲基取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的用途
EP2231645B1 (de) 2007-12-07 2012-10-03 Abbott GmbH & Co. KG 5-Halogen-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
JP5323088B2 (ja) 2007-12-18 2013-10-23 アクテリオン ファーマシューティカルズ リミテッド ５−アミノシクリルメチル−オキサゾリジン−２−オン誘導体
CN102056933B (zh) 2008-04-11 2014-09-17 詹森药业有限公司 作为白三烯a4水解酶调节剂的噻唑并吡啶-2-基氧基-苯基和噻唑并吡嗪-2-基氧基-苯基胺类
US8148408B2 (en) * 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
EP2411012A4 (en) * 2009-03-24 2012-08-22 Msd Kk NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE INHIBITORY ACTION OF AURORA A
EP2430019B1 (en) 2009-05-14 2013-09-18 Janssen Pharmaceutica, N.V. Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
US8785440B2 (en) 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
EP3093291B1 (en) 2009-10-23 2019-05-08 Janssen Pharmaceutica NV Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
US9062044B2 (en) * 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
EP2491034B1 (en) * 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
MX2017005484A (es) 2014-10-31 2017-10-20 Indivior Uk Ltd Compuestos antagonistas del receptor de dopamina d3.
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
EP3686196B1 (en) * 2017-09-20 2024-06-12 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
EA202191356A1 (ru) 2018-11-14 2021-08-11 Янссен Фармацевтика Нв Усовершенствованные способы синтеза для получения конденсированных гетероциклических соединений в качестве модуляторов рецептора орексина
US20220227773A1 (en) * 2019-05-30 2022-07-21 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Fused ring compound, preparation method therefor and use thereof
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393424B1 (de) * 1989-04-17 1995-09-27 Bayer Ag Verfahren zur Herstellung von 2,7-Diazabicyclo(3.3.0)octanen
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
CA2112165C (en) 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JP4176147B2 (ja) * 1995-07-28 2008-11-05 アボツト・ラボラトリーズ 化学的シナプス伝達の制御に有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
CZ298824B6 (cs) * 1997-05-30 2008-02-20 Neurosearch A/S Deriváty 8-azabicyklo[3.2.1]okt-2-enu, zpusob jejich prípravy a jejich použití
DK0984966T3 (da) * 1997-05-30 2003-05-05 Neurosearch As 9-azabicyclo[3.3.1]non-2-en derivater, som er cholinerge ligander på nikotin-ACh receptorer
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
SK285198B6 (sk) * 1997-10-27 2006-08-03 Neurosearch A/S Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
MXPA00009634A (es) * 1998-04-02 2005-06-20 Targacept Inc Derivados de azatriciclo[3.3.1.1]decano y composiciones farmaceuticas que los contienen.
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
TR200102162T2 (tr) * 1999-01-29 2001-12-21 Abbott Laboratories Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler.
NZ513575A (en) * 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
SI1178982T1 (en) * 1999-05-21 2004-12-31 Abbott Laboratories Heterocyclic substituted aminoazacycles useful as central nervous system agents
DE60018312T2 (de) * 1999-12-14 2005-08-18 Neurosearch A/S Neue heteroaryl-diazabizykloalkane

Also Published As

Publication number Publication date
CZ302795B6 (cs) 2011-11-16
CN1440410A (zh) 2003-09-03
EP2298775A1 (en) 2011-03-23
TWI323733B (en) 2010-04-21
MY145722A (en) 2012-03-30
BG66151B1 (bg) 2011-08-31
PL398491A1 (pl) 2012-06-04
CN101935322A (zh) 2011-01-05
SK287273B6 (sk) 2010-05-07
MY137020A (en) 2008-12-31
NO324250B1 (no) 2007-09-17
KR20090013833A (ko) 2009-02-05
NZ521734A (en) 2004-10-29
TWI357903B (en) 2012-02-11
HUP0300602A2 (hu) 2003-06-28
SK287658B6 (sk) 2011-05-06
KR100947188B1 (ko) 2010-03-12
HUP0300602A3 (en) 2005-12-28
AU6655901A (en) 2001-11-07
TW200617013A (en) 2006-06-01
CZ301324B6 (cs) 2010-01-13
NO20025107L (no) 2002-12-19
JP4981232B2 (ja) 2012-07-18
PE20011305A1 (es) 2001-12-31
CZ302072B6 (cs) 2010-09-29
KR100961406B1 (ko) 2010-06-09
BG107303A (bg) 2003-07-31
AU2001266559B2 (en) 2005-03-03
AU2001266559C1 (en) 2005-11-17
TWI311137B (en) 2009-06-21
JP2003531210A (ja) 2003-10-21
TW200909432A (en) 2009-03-01
PL358340A1 (en) 2004-08-09
MY168244A (en) 2018-10-15
SK16812002A3 (sk) 2003-04-01
NO20025107D0 (no) 2002-10-24
TW201141871A (en) 2011-12-01
IL177316A (en) 2010-06-30
MXPA02010594A (es) 2003-05-14
CZ302038B6 (cs) 2010-09-15
CA2407094C (en) 2009-11-17
EP2295437A1 (en) 2011-03-16
BR0107246A (pt) 2002-10-01
HK1054375A1 (zh) 2003-11-28
IL203035A (en) 2010-12-30
BG110620A (bg) 2010-07-30
KR20090121385A (ko) 2009-11-25
AR030421A1 (es) 2003-08-20
WO2001081347A2 (en) 2001-11-01
WO2001081347A3 (en) 2002-01-31
CZ20023765A3 (cs) 2003-02-12
CN100430398C (zh) 2008-11-05
KR100899950B1 (ko) 2009-05-28
KR20090071654A (ko) 2009-07-01
IL177316A0 (en) 2006-12-10
CA2683045A1 (en) 2001-11-01
CA2407094A1 (en) 2001-11-01
JP2012041349A (ja) 2012-03-01
KR20020093955A (ko) 2002-12-16
KR100947187B1 (ko) 2010-03-12
EP1284976A2 (en) 2003-02-26
CN102863441A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
IL177316A0 (en) Diazabicyclic central nervous system active agents
MXPA02002898A (es) Pirazolopirimidinas como agentes terapeuticos.
GB0012671D0 (en) Therapeutic agents
GB0003397D0 (en) Therapeutic agents
GB0004003D0 (en) Therapeutic agents
TW526820U (en) Seat
GB0005789D0 (en) Therapeutic agents
GB0007907D0 (en) Therapeutic agents
GB0012214D0 (en) Therapeutic agents
GB0008696D0 (en) Therapeutic agents
GB0000564D0 (en) Therapeutic agents
GB0007376D0 (en) Therapeutic agents
GB2366722B (en) Bath seat
GB2369991B (en) Seating system
GB0025133D0 (en) Seat system
TW458389U (en) Battery seat
TW452210U (en) Battery seat structure
GB9905034D0 (en) Antidiuretic agents
GB2352622B (en) Seat
CA87281S (en) Shower-batch seat
GB9924171D0 (en) Seat
GB9910342D0 (en) Seat
GB9925792D0 (en) Seat
SI1212327T1 (en) Pyrazolopyrimidines as therapeutic agents
TW452209U (en) Battery seat

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees